Credit: Pfizer. Patients should be selected for treatment based on the presence of HRR gene mutations. The Food and Drug Administration (FDA) has approved Talzenna ® (talazoparib), in combination with ...

Significant improvement in radiographic progression-free survival seen first in BRCA subgroup. HealthDay News — For patients with metastatic castration-sensitive prostate cancer (mCSPC) with ...

New data suggest that olaparib without ADT could be a reasonable treatment strategy in selected patients with high-risk prostate cancer that recurs after radical prostatectomy. Olaparib monotherapy ...

The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior ...

LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner Prostate cancer is the second most common ...

Almost 28% of men with metastatic castration-resistant prostate cancer harbor alterations in homologous recombination repair genes, a study found. New findings support for the first time the use of ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for ...

Talazoparib in combination with enzalutamide showed a 55% reduction in the risk of disease progression or death for patients with metastatic castration-resistant prostate cancer (mCRPC) with ...

Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US). This is an ...